The Therapeutic Goods
Administration (TGA) has added
GSK’s Tafinlar (dabrafenib mesilate)
a treatment for a specific form
of melanoma, and Specialised
Therapeutics Australia’s Aloxi
(palonosetron hydrochloride)
which is indicated for prevention
of nausea and vomiting induced
by cytotoxic chemotherapy, to
the Australian Public Assessment
Report (AusPARS).
CLICK HERE for details.The above article was sent to subscribers in Pharmacy Daily's issue from 14 Jan 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Jan 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.